<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02797314</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16_0092</org_study_id>
    <nct_id>NCT02797314</nct_id>
  </id_info>
  <brief_title>Comparison of Bone Quality in Type 2 Diabetic Patients With a Non-diabetic Control Population</brief_title>
  <acronym>DIABONE</acronym>
  <official_title>Comparison of Bone Quality in Type 2 Diabetic Patients With a Non-diabetic Control Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with type 2 diabetes have many complications in different organs. These
      complications are extremely frequent and severe: cardiovascular and renal disease, visual
      impairment, and, more recently, complications affecting bone such as fractures. Conventional
      methods for the evaluation of fracture risk are based on the Bone Mineral Density (BMD) or
      FRAX (algorithm for the prediction of osteoporotic fracture risk) are not sufficient in the
      context of diabetes. Several metaanalyses have shown that, paradoxically, a higher BMD in
      patients with type 2 diabetes compared to patients not suffering from this disease,
      independently of body mass index (BMI). The paradoxal increase in fracture risk, despite a
      high BMD has led to the hypothesis that diabetes induces a modification of the quality and
      not the quantity of bone. However, there is a lack of data as to bone quality in patients
      with type 2 diabetes as studies of bone biopsies from patients with type 2 diabetes are
      extremely rare.

      The objective of the study is to compare bone quality in patients with type 2 diabetes to
      that in patients who do not suffer from type 2 diabetes: evaluation of vertebral fractures by
      osteodensitometry, measurement of Trabecular Bone Score (TBS), and analysis of bone quality
      in biopsies (advanced glycation end products (AGE), contents of bone matrix and analysis of
      mineralization).

      The results will then be correlated with blood/urinary markers with the objective to
      determine one/several non-invasive biomarkers for bone status in diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2017</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>1 month after patient inclusion</time_frame>
    <description>Bone mineral density (BMD) measured by Dual-energy X-ray absorptiometry (DXA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vertebral fractures</measure>
    <time_frame>1 month after patient inclusion</time_frame>
    <description>Presence of vertebral fractures evaluated by Vertebral Fracture Assessment (VFA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trabecular Bone Score</measure>
    <time_frame>1 month after patient inclusion</time_frame>
    <description>Trabecular bone score (TBS) is a analytical tool that performs novel grey-level texture measurements on lumbar spine dual X-ray absorptiometry (DXA) images, and thereby captures information relating to trabecular microarchitecture</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Type 2 diabetic population</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Bone biopsies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-diabetic control population</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Bone biopsies</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bone biopsies</intervention_name>
    <description>Bone biopsies</description>
    <arm_group_label>Type 2 diabetic population</arm_group_label>
    <arm_group_label>Non-diabetic control population</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged greater than 40 years

          -  Patients requiring surgery of the lower limb

          -  With a bone mineral density considered normal (T-score ≥ -1,5)

          -  Stage 1, 2, or 3 glomerular filtration rate (&gt; 30 mL/min)

          -  For diabetic patients the diagnosis will have previously established by an
             endocrinologist

        Exclusion Criteria:

          -  Subjects treated with drugs known to interfere with bone metabolism, including
             steroids, anticonvulsants, diuretics, and bisphosphonates

          -  Patients with severe renal disease (&lt; 30 ml/mn); previous history of caner except skin
             cancer; myocardial infarction; uncontrolled hypertension; untreated hyperthyroidism;
             hyperthyroidism; malabsorption; bone metabolism diseases; rheumatoid arthritis or
             collagen diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julien WEGRZYN, MD</last_name>
    <phone>4 72 11 04 43</phone>
    <phone_ext>+33</phone_ext>
    <email>julien.wegrzyn@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Delphine FARLAY</last_name>
    <phone>4 78 77 57 35</phone>
    <phone_ext>+33</phone_ext>
    <email>delphine.farlay@inserm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot, Hospices Civisl de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien WEGRZYN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Julien WEGRZYN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord, CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Hélène LAFAGE-PROUST, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marie-Hélène LAFAGE-PROUST, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2016</study_first_submitted>
  <study_first_submitted_qc>June 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2016</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Bone quality</keyword>
  <keyword>Bone biopsies</keyword>
  <keyword>Vertebral fractures</keyword>
  <keyword>Osteodensitometry</keyword>
  <keyword>Trabecular Bone Score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

